Alexion Rare Disease to invest $68.9 Million in Manufacturing, R&D in Ireland

Alexion, AstraZeneca’s rare disease group will invest $68.9 million (€65 million) in new and enhanced capabilities for manufacturing, and research and development across its sites in Ireland.

Photo: Marc Dunoyer, CEO of Alexion

The program will center on three investments: the installation of new drug substance production equipment and warehousing facilities to support ambient and cold storage at both sites in College Park and Athlone; and the construction of a Manufacturing Sciences & Technology Lab at College Park.

The equipment and warehouse facility in each site will expand Alexion’s drug substance production capabilities in Ireland. The Alexion Manufacturing Sciences & Technology Lab at College Park will facilitate scaling up of biologics drug substance manufacturing in Ireland.

This investment in Ireland follows last year’s announcement to build a next generation active pharmaceutical ingredient facility at AstraZeneca’s College Park campus.

“This investment will allow for new capabilities for AstraZeneca in Ireland and support our global ambition to accelerate the development and delivery of life-changing medicines for more people affected by rare diseases,” said Marc Dunoyer, CEO of Alexion. 

Author: Rare Daily Staff